Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746124 | 0.98 | TDP1 (0.47) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| SCHEMBL27550187 | 0.98 | TDP1 (0.47) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| SCHEMBL5745538 | 0.98 | TDP1 (0.47) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| SCHEMBL27524862 | 0.98 | TDP1 (0.47) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| SCHEMBL5748952 | 0.98 | TDP1 (0.47) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| SCHEMBL510211 | 0.94 | CYP2C9 (0.43) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| Hydrochloric Acid SCHEMBL28992846 | 0.93 | CYP2C9 (0.42) | TDP1L3MBTL1PDPK1CYP1A2CYP2C9 | |
| SCHEMBL28506433 | 0.89 | CYP1A2 (0.41) | TDP1L3MBTL1PDPK1DHFRCYP1A2 | |
| SCHEMBL1093436 | 0.86 | NOS2 (0.40) | L3MBTL1PDPK1DHFRCYP1A2CYP2C9 | |
| SCHEMBL29806076 | 0.86 | NOS2 (0.40) | L3MBTL1PDPK1DHFRCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-20200140453-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-07 | — | — | US | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3145507-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | Musc Foundation for Research Development (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | disclosed |
| CN-103153300-A | Heteroaryls and uses thereof | MILLENNIUM PHARM INC | 2013-06-12 | — | — | CN | disclosed |
| CN-102395585-A | Heteroaryls and their use as pi3k inhibitors | MILLENNIUM PHARM INC | 2012-03-28 | — | — | CN | disclosed |
| WO-2007075630-A1 | METHOD FOR PRODUCING 3-AMINOPIPERIDINE DIASTEREOMER | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| JP-2001068270-A | ORGANIC ELECTROLUMINESCENCE ELEMENT | MITSUI CHEMICALS INC | 2001-03-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | AZI2, DNMT1, TET3 | TDP1 1327/4885L3MBTL1 4845/4885PDPK1 1221/4885 |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | AZI2, DNMT1, TET3 | TDP1 1327/4885L3MBTL1 4845/4885PDPK1 1221/4885 |
| US-20200140453-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | TDP1 2913/4885L3MBTL1 4199/4885PDPK1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.